Word: lymphomas
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...best, only half of those children were expected to see their teens. But today, 1 in 1,000 young adults in the U.S. is a childhood-cancer survivor. Since the 1970s, the chance that a child would live for five years after a diagnosis of leukemia or lymphoma, the most common childhood cancers, has risen steadily, from an average of 25% to more than 80% today, outpacing recovery rates for most adult cancers...
Serious heart disease, however, can be prevented with the right screening and follow-up care, and the same is true for many of the other severe health problems that can emerge years after cancer treatments. In previous decades, for instance, girls with Hodgkin's lymphoma were frequently treated with radiation to the chest, putting them at increased risk of developing breast cancer as young women. Screening them at age 25 instead of 40, as usually recommended, can pick up the disease sooner and, it is hoped, give doctors the chance to remove small lesions before they grow or spread. (Radiation...
...That is not to say Thompson hasn't had to overcome many personal hardships - a marriage while in high school after conceiving a child with his teenage girlfriend, a subsequent divorce, a diagnosis of non-Hodgkin's lymphoma 2 1/2 years ago and, perhaps most traumatic, the sudden death of his daughter Betsy in 2002 from an accidental overdose of prescription drugs. He is now married to a Republican political strategist and has two small children...
...everyone is convinced by that logic. Dr. Robert Schwartz, an editor at the New England Journal of Medicine, says, "Using patients as their own control is a bit shaky, especially for follicular lymphoma." A Phase III randomized trial, more difficult but still possible to conduct even with customized vaccines remains, he says, "the gold standard for proof of efficacy." Dr. Kwak, who is conducting his own Phase III trial of a vaccine for the American pharmaceutical company Biovest, believes his former trainee's results support the case for a therapeutic lymphoma vaccine, but is skeptical about his methods. "Dr. Bendandi...
...patient relapsed while receiving the vaccine, it would have been over. I would have needed a new job," he jokes. But the Italian-born physician is still working. In a few weeks he starts his new study, which is designed to test the vaccine's effectiveness in follicular lymphoma patients with an especially poor prognosis. Bendandi plans to administer the vaccine to participants until they relapse or die from a cause other than lymphoma. "This time," he says, "I'm going after a cure...